Alternative Data for Celldex Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 16 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 168 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,720 | Sign up | Sign up | Sign up |
| X Followers | 186 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 79 | Sign up | Sign up | Sign up |
| Linkedin Employees | 248 | Sign up | Sign up | Sign up |
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
| Price | $28.90 |
| Target Price | Sign up |
| Volume | 1,273,657 |
| Market Cap | $2.25B |
| Year Range | $22.58 - $34.55 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 6 - GlobeNewswire |
|
 |
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading PerformanceJanuary 28 - Yahoo |
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsightJune 4 - GlobeNewswire |
|
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)May 18 - GlobeNewswire |
|
Celldex Reports First Quarter Financial Results and Provides Corporate UpdateMay 7 - GlobeNewswire |
|
Bi-Specific MAbS Market Research Report 2026: $21.83 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FMay 7 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 15,000 | 0 | 0 | -79M | 0 | -1.180 |
| Q4 '25 | 75,000 | 0 | 75,000 | -81M | -81M | -1.220 |
| Q3 '25 | 0 | 63M | -63M | -67M | -73M | -1.010 |
| Q2 '25 | 730,000 | 0 | 730,000 | -57M | -63M | -0.850 |
| Q1 '25 | 700,000 | 0 | 700,000 | -54M | -62M | -0.810 |
Insider Transactions View All
| Jimenez Freddy A. filed to sell 30,796 shares at $29.1. December 8 '25 |
| Wright Richard M. filed to sell 20,833 shares at $24. November 17 '25 |
| Jimenez Freddy A. filed to sell 35,392 shares at $24. August 15 '25 |
| Jimenez Freddy A. filed to sell 34,962 shares at $25.4. August 15 '25 |
| Marucci Anthony S filed to buy 40,284 shares at $26.8. November 12 '24 |
Similar companies
Read more about Celldex Therapeutics (CLDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Celldex Therapeutics
The Market Cap of Celldex Therapeutics is $2.25B.
Currently, the price of one share of Celldex Therapeutics stock is $28.90.
The CLDX stock price chart above provides a comprehensive visual representation of Celldex Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Celldex Therapeutics shares. Our platform offers an up-to-date CLDX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Celldex Therapeutics (CLDX) does not offer dividends to its shareholders. Investors interested in Celldex Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Celldex Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
